News - Pharmaceuticals
Sustainable Pharma companies outperform peers

Pharma News: Only four global pharmaceutical companies rank in the 2021 Global 100 Most Sustainable Corporations – Eisai, AstraZeneca, Takeda and Sanofi.
The Global 100 index evaluates the sustainability of more than 8,000 of the world’s major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance).
Ranked 16th, Eisai was the highest ranking company among global pharmaceutical companies.
Takeda is proud to be ranked in the Global 100 index for the fifth consecutive year.
“Building sustainable value is a fundamental part of the way we do business at Takeda, and we are proud to be recognized as a global leader in sustainability,” said Christophe Weber, Takeda President and CEO. “This recognition by Corporate Knights is a testament to the strong foundation Takeda has laid and the progress we have already achieved. We remain steadfast in our commitment to realizing Better Health and a Brighter Future for all.”
Despite the economic impact of the COVID-19 crisis, governments around the world have seized on the opportunity presented by the need to kick-start their economies and add green investments into their stimulus plans.
The Global 100 index continues to demonstrate that sustainability is good business and enables companies to outperform their peers.
From its inception on February 1, 2005, to December 31, 2020, the Global 100 index has generated a total return of 263% versus the 220% increase of its benchmark, the MSCI ACWI (All Country World Index). For the calendar year 2020, the Global 100 was up 26% compared with a rise of 16% for the MSCI ACWI.
Global 100 companies are also more gender-diverse than their peers, with almost a third of board directors (32%) being non-male against 24% for MSCI ACWI companies.
Sustainability is now central to doing business, as the Global 100’s continuing superior performance highlights.
News - MedTech & Diagnostics
Hearts4heart takes aim at health insurers leaving patients to pay the price
Persistent advocacy by patient groups has prompted the Medical Services Advisory Committee (MSAC) to review the funding gaps for pulsed […]
MoreNews - MedTech & Diagnostics
Queensland first: Private hospitals deploy Abbott’s PFA in atrial fibrillation
More Australians living with atrial fibrillation (AF) are gaining access to one of the latest advances in heart-rhythm treatment, with […]
MoreNews - Pharmaceuticals
Five years of HTA reform talk, now comes the $47 billion question
Medicines Australia has put a $47 billion price tag on what it says Australia must invest to improve equitable access […]
MoreNews - Pharmaceuticals
New MFN deals raise the stakes for Australia’s delayed HTA reform
Four months after the US Trump administration concluded what was expected to be the final tranche of drug-pricing agreements with […]
More